The molecular mechanism of amyloid β42 peptide toxicity: The role of sphingosine kinase-1 and mitochondrial sirtuins

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Cies̈lik, Magdalena ^a   Czapski, Grzegorz A ^a   Strosznajder, Joanna B ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOPTOSIS INDUCING FACTOR; CATALASE; GLYCOGEN SYNTHASE KINASE 3BETA; MANGANESE SUPEROXIDE DISMUTASE; PROTEIN P53; QUERCETIN; RESVERATROL; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SPHINGOSINE KINASE 1; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT; PHOSPHOTRANSFERASE; SIRTUIN; SPHINGOSINE KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; METABOLISM; MITOCHONDRION; PC12 CELL LINE;

AMYLOID BETA-PEPTIDES; ANIMALS; MITOCHONDRIA; PC12 CELLS; PEPTIDE FRAGMENTS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); RATS; SIRTUINS;

EID: 84947475250     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137193     Document Type: Article

References (65)

1. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992; 256: 184-185. PMID: 1566067
2. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006; 440: 352-357. PMID: 16541076
3. Sery O, Povova J, Misek I, Pesak L, Janout V. Molecular mechanisms of neuropathological changes in Alzheimer's disease: a review. Folia Neuropathol. 2013; 51: 1-9. PMID: 23553131
4. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999; 46: 860-866. PMID: 10589538
5. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003; 4: 397-407. PMID: 12728273
6. Couttas TA, Kain N, Daniels B, Lim XY, Shepherd C, Kril J, et al. Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathol Commun. 2014; 2: 9. doi: 10.1186/2051-5960-2-9 PMID: 24456642
7. Fonteh AN, Ormseth C, Chiang J, Cipolla M, Arakaki X, Harrington MG. Sphingolipid metabolism correlates with cerebrospinal fluid Beta amyloid levels in Alzheimer's disease. PloS one. 2015; 10: e0125597. doi: 10.1371/journal.pone.0125597 PMID: 25938590
8. Han X, D MH, McKeel DW Jr., Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem. 2002; 82: 809-818. PMID: 12358786
9. Li NJ, Liu WT, Li W, Li SQ, Chen XH, Bi KS, et al. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin Biochem. 2010; 43: 992-997. doi: 10.1016/j. clinbiochem.2010.04.072 PMID: 20457143
10. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging. 2010; 31: 398-408. doi: 10.1016/j.neurobiolaging.2008.05.010 PMID: 18547682
11. Ceccom J, Loukh N, Lauwers-Cances V, Touriol C, Nicaise Y, Gentil C, et al. Reduced sphingosine kinase-1 and enhanced sphingosine 1-phosphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease. Acta Neuropathol Commun. 2014; 2: 12. doi: 10. 1186/2051-5960-2-12 PMID: 24468113
12. Takasugi N, Sasaki T, Suzuki K, Osawa S, Isshiki H, Hori Y, et al. BACE1 activity is modulated by cellassociated sphingosine-1-phosphate. J Neurosci. 2011; 31: 6850-6857. doi: 10.1523/JNEUROSCI. 6467-10.2011 PMID: 21543615
13. Asle-Rousta M, Kolahdooz Z, Oryan S, Ahmadiani A, Dargahi L. FTY720 (fingolimod) attenuates betaamyloid peptide (Abeta42)-induced impairment of spatial learning and memory in rats. J Mol Neurosci. 2013; 50: 524-532. doi: 10.1007/s12031-013-9979-6 PMID: 23435938
14. Gassowska M, Cieslik M, Wilkaniec A, Strosznajder JB. Sphingosine kinases/sphingosine-1-phosphate and death Signalling in APP-transfected cells. Neurochem Res. 2014; 39: 645-652. doi: 10. 1007/s11064-014-1240-3 PMID: 24452756
15. Yang Y, Wang M, Lv B, Ma R, Hu J, Dun Y, et al. Sphingosine kinase-1 protects differentiated N2a cells against beta-amyloid25-35-induced neurotoxicity via the mitochondrial pathway. Neurochem Res. 2014; 39: 932-940. doi: 10.1007/s11064-014-1290-6 PMID: 24682752
16. Jesko H, Okada T, Strosznajder RP, Nakamura S. Sphingosine kinases modulate the secretion of amyloid beta precursor protein from SH-SY5Y neuroblastoma cells: the role of alpha-synuclein. Folia Neuropathol. 2014; 52: 70-78. PMID: 24729344
17. Karaca I, Tamboli IY, Glebov K, Richter J, Fell LH, Grimm MO, et al. Deficiency of sphingosine-1-phosphate lyase impairs lysosomal metabolism of the amyloid precursor protein. J Biol Chem. 2014; 289: 16761-16772. doi: 10.1074/jbc.M113.535500 PMID: 24808180
18. Yuyama K, Mitsutake S, Igarashi Y. Pathological roles of ceramide and its metabolites in metabolic syndrome and Alzheimer's disease. Biochim Biophys Acta. 2014; 1841: 793-798. doi: 10.1016/j.bbalip. 2013.08.002 PMID: 23948264
19. Czubowicz K, Strosznajder R. Ceramide in the molecular mechanisms of neuronal cell death. The role of sphingosine-1-phosphate. Mol Neurobiol. 2014; 50: 26-37. doi: 10.1007/s12035-013-8606-4 PMID: 24420784
20. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000; 403: 795-800. PMID: 10693811
21. Tanny JC, Dowd GJ, Huang J, Hilz H, Moazed D. An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing. Cell. 1999; 99: 735-745. PMID: 10619427
22. He W, Newman JC, Wang MZ, Ho L, Verdin E. Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol Metab. 2012; 23: 467-476. doi: 10.1016/j.tem.2012.07.004 PMID: 22902903
23. Peng C, Lu Z, Xie Z, Cheng Z, Chen Y, Tan M, et al. The first identification of lysine malonylation substrates and its regulatory enzyme. Mol Cell Proteomics. 2011; 10: M111 012658.
24. Herskovits AZ, Guarente L. Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res. 2013; 23: 746-758. doi: 10.1038/cr.2013.70 PMID: 23689277
25. Jiang M, Wang J, Fu J, Du L, Jeong H, West T, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat Med. 2012; 18: 153-158.
26. Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L. SIRT1 protects against alphasynuclein aggregation by activating molecular chaperones. J Neurosci. 2012; 32: 124-132. doi: 10. 1523/JNEUROSCI.3442-11.2012 PMID: 22219275
27. Green KN, Steffan JS, Martinez-Coria H, Sun X, Schreiber SS, Thompson LM, et al. Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci. 2008; 28: 11500-11510. doi: 10.1523/ JNEUROSCI.3203-08.2008 PMID: 18987186
28. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007; 26: 3169-3179. PMID: 17581637
29. Kincaid B, Bossy-Wetzel E. Forever young: SIRT3 a shield against mitochondrial meltdown, aging, and neurodegeneration. Front Aging Neurosci. 2013; 5: 48. doi: 10.3389/fnagi.2013.00048 PMID: 24046746
30. Cheng Y, Ren X, Gowda AS, Shan Y, Zhang L, Yuan YS, et al. Interaction of Sirt3 with OGG1 contributes to repair of mitochondrial DNA and protects from apoptotic cell death under oxidative stress. Cell Death Dis. 2013; 4: e731. doi: 10.1038/cddis.2013.254 PMID: 23868064
31. Bonda DJ, Lee HG, Camins A, Pallas M, Casadesus G, Smith MA, et al. The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol. 2011; 10: 275-279. doi: 10.1016/S1474-4422(11)70013-8 PMID: 21349442
32. Donmez G, Wang D, Cohen DE, Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell. 2010; 142: 320-332. doi: 10.1016/j.cell.2010.06.020 PMID: 20655472
33. Stine WB Jr., Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003; 278: 11612-11622. PMID: 12499373
34. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A. 1976; 73: 2424-2428. PMID: 1065897
35. Fornai F, Lenzi P, Lazzeri G, Ferrucci M, Fulceri F, Giorgi FS, et al. Fine ultrastructure and biochemistry of PC12 cells: a comparative approach to understand neurotoxicity. Brain Res. 2007; 1129: 174-190. PMID: 17157274
36. Pyszko JA, Strosznajder JB. The key role of sphingosine kinases in the molecular mechanism of neuronal cell survival and death in an experimental model of Parkinson's disease. Folia Neuropathol. 2014; 52: 260-269. PMID: 25310737
37. Hooper C, Meimaridou E, Tavassoli M, Melino G, Lovestone S, Killick R. p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett. 2007; 418: 34-37. PMID: 17399897
38. Gandy KA, Obeid LM. Regulation of the sphingosine kinase/sphingosine 1-phosphate pathway. Handb Exp Pharmacol. 2013: 275-303. doi: 10.1007/978-3-7091-1511-4-14 PMID: 23563662
39. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem. 2008; 104: 1433-1439. PMID: 18088381
40. Kitagishi Y, Nakanishi A, Ogura Y, Matsuda S. Dietary regulation of PI3K/AKT/GSK-3beta pathway in Alzheimer's disease. Alzheimers Res Ther. 2014; 6: 35. doi: 10.1186/alzrt265 PMID: 25031641
41. Czapski GA, Gassowska M, Songin M, Radecka UD, Strosznajder JB. Alterations of cyclin dependent kinase 5 expression and phosphorylation in amyloid precursor protein (APP)-transfected PC12 cells. FEBS Lett. 2011; 585: 1243-1248. doi: 10.1016/j.febslet.2011.03.058 PMID: 21457712
42. Jimenez S, Torres M, Vizuete M, Sanchez-Varo R, Sanchez-Mejias E, Trujillo-Estrada L, et al. Agedependent accumulation of soluble amyloid beta (Abeta) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model. J Biol Chem. 2011; 286: 18414-18425. doi: 10.1074/jbc.M110.209718 PMID: 21460223
43. Nassif M, Hoppe J, Santin K, Frozza R, Zamin LL, Simao F, et al. Beta-amyloid peptide toxicity in organotypic hippocampal slice culture involves Akt/PKB, GSK-3beta, and PTEN. Neurochem Int. 2007; 50: 229-235. PMID: 17018242
44. Cedazo-Minguez A, Popescu BO, Blanco-Millan JM, Akterin S, Pei JJ, Winblad B, et al. Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta. J Neurochem. 2003; 87: 1152-1164. PMID: 14622095
45. Cieslik M, Pyszko J, Strosznajder JB. Docosahexaenoic acid and tetracyclines as promising neuroprotective compounds with poly(ADP-ribose) polymerase inhibitory activities for oxidative/genotoxic stress treatment. Neurochem Int. 2013; 62: 626-636. doi: 10.1016/j.neuint.2013.02.016 PMID: 23439385
46. Strosznajder JB, Czapski GA, Adamczyk A, Strosznajder RP. Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease. Mol Neurobiol. 2012; 46: 78-84. doi: 10.1007/s12035-012- 8258-9 PMID: 22430645
47. Andrabi SA, Dawson TM, Dawson VL. Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann N Y Acad Sci. 2008; 1147: 233-241. doi: 10.1196/annals.1427.014 PMID: 19076445
48. de Moura MB, Uppala R, Zhang Y, Van Houten B, Goetzman ES. Overexpression of mitochondrial sirtuins alters glycolysis and mitochondrial function in HEK293 cells. PloS one. 2014; 9: e106028. doi: 10. 1371/journal.pone.0106028 PMID: 25165814
49. Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell. 2011; 44: 177-190. doi: 10.1016/j.molcel.2011.07.019 PMID: 21856199
50. Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science. 2011; 334: 806-809. doi: 10.1126/science.1207861 PMID: 22076378
51. Culmsee C, Mattson MP. p53 in neuronal apoptosis. Biochem Biophys Res Commun. 2005; 331: 761-777. PMID: 15865932
52. Kazmierczak A, Czapski GA, Adamczyk A, Gajkowska B, Strosznajder JB. A novel mechanism of non- Abeta component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). Neurochem Int. 2011; 58: 206-214. doi: 10.1016/j.neuint.2010. 11.018 PMID: 21130128
53. Buizza L, Prandelli C, Bonini SA, Delbarba A, Cenini G, Lanni C, et al. Conformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth-associated protein 43 expression. Cell Death Dis. 2013; 4: e484. doi: 10.1038/cddis.2013.13 PMID: 23392172
54. Aubry S, Shin W, Crary JF, Lefort R, Qureshi YH, Lefebvre C, et al. Assembly and interrogation of Alzheimer's disease genetic networks reveal novel regulators of progression. PloS one. 2015; 10: e0120352. doi: 10.1371/journal.pone.0120352 PMID: 25781952
55. Nakanishi A, Minami A, Kitagishi Y, Ogura Y, Matsuda S. BRCA1 and p53 tumor suppressor molecules in Alzheimer's disease. Int J Mol Sci. 2015; 16: 2879-2892. doi: 10.3390/ijms16022879 PMID: 25636033
56. Koczor CA, White RC, Zhao P, Zhu L, Fields E, Lewis W. p53 and mitochondrial DNA: their role in mitochondrial homeostasis and toxicity of antiretrovirals. Am J Pathol. 2012; 180: 2276-2283. doi: 10.1016/ j.ajpath.2012.01.045 PMID: 22469844
57. Pyszko J, Strosznajder JB. Sphingosine kinase 1 and sphingosine-1-phosphate in oxidative stress evoked by 1-methyl-4-phenylpyridinium (MPP+) in human dopaminergic neuronal cells. Mol Neurobiol. 2014; 50: 38-48. doi: 10.1007/s12035-013-8622-4 PMID: 24399507
58. van Echten-Deckert G, Hagen-Euteneuer N, Karaca I, Walter J. Sphingosine-1-phosphate: boon and bane for the brain. Cell Physiol Biochem. 2014; 34: 148-157. doi: 10.1159/000362991 PMID: 24977488
59. Hemmati F, Dargahi L, Nasoohi S, Omidbakhsh R, Mohamed Z, Chik Z, et al. Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: comparison with memantine. Behav Brain Res. 2013; 252: 415-421. doi: 10.1016/j.bbr.2013.06.016 PMID: 23777795
60. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010; 1802: 396-405. doi: 10.1016/j.bbadis.2009.12.009 PMID: 20079433
61. Perry G, Roder H, Nunomura A, Takeda A, Friedlich AL, Zhu X, et al. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport. 1999; 10: 2411-2415. PMID: 10439473
62. Masliah E, Cole GM, Hansen LA, Mallory M, Albright T, Terry RD, et al. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. J Neurosci. 1991; 11: 2759-2767. PMID: 1880547
63. Kim T, Hinton DJ, Choi DS. Protein kinase C-regulated abeta production and clearance. Int J Alzheimers Dis. 2011; 2011: 857368. doi: 10.4061/2011/857368 PMID: 21274428
64. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov. 2012; 11: 937-957. doi: 10.1038/nrd3871 PMID: 23197040
65. Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer's disease. Current pharmaceutical design. 2012; 18: 27-33. PMID: 22211686